NAD Controls the Off Switch for Blood Vessel Growth — and May Fight Cancer
New research reveals NAD metabolism governs how blood vessels stabilize after growth, with implications for cancer and eye disease.
Summary
Blood vessels don't just grow — they also need to stop growing and stabilize. This study from the University of Pennsylvania reveals that NAD, a molecule central to cellular energy and longevity research, plays a critical role in this stabilization process. When endothelial cells (the cells lining blood vessels) transition from active proliferation back to a resting state, they become vulnerable to oxidative stress. NAD protects them by suppressing excess hydrogen peroxide produced by mitochondria. Without adequate NAD, vessels sprout but fail to mature into stable networks. Crucially, blocking NAD synthesis in disease models reduced abnormal blood vessel growth in retinopathy and tumors — suggesting that targeting this pathway could offer a new strategy for treating cancers and blinding eye diseases.
Detailed Summary
Blood vessel formation, or angiogenesis, is a tightly choreographed process essential for tissue repair, development, and — when dysregulated — cancer progression and diabetic eye disease. While scientists have extensively studied how vessels start growing, far less is known about how they stop and stabilize. This study addresses that gap by identifying NAD-dependent redox control as a key mechanism governing the return of endothelial cells from proliferation to quiescence.
Researchers at the University of Pennsylvania used in vitro, ex vivo, and in vivo models to dissect what happens metabolically when endothelial cells transition from active growth back to a resting state. They found that this transition — termed proliferation-to-quiescence (PtoQ) — involves a metabolic rewiring that makes cells acutely sensitive to oxidative stress, specifically mitochondria-derived hydrogen peroxide (H2O2).
NAD turnover proved essential for neutralizing this oxidative threat. When NAD availability was restricted, endothelial cells could still proliferate and migrate normally, but they failed to form stable cell-cell contacts and could not complete the quiescence transition. In living tissue models, NAD-deficient vessels sprouted but could not form mature, stable vascular networks. Conversely, removing excess H2O2 rescued the quiescence process, confirming that NAD's protective role operates through redox suppression.
The therapeutic implications are significant. In mouse models of oxygen-induced retinopathy and tumor angiogenesis, inhibiting NAD synthesis curtailed pathological blood vessel overgrowth — the kind that drives vision loss and fuels tumor growth. This positions NAD biosynthesis inhibition as a potential anti-angiogenic strategy distinct from existing VEGF-targeting therapies.
Caveats include that the full study details are unavailable (abstract only), and translating these findings to human therapeutics will require careful dose optimization, given NAD's broad roles in cellular metabolism and its current popularity as a longevity supplement.
Key Findings
- NAD is required for blood vessels to stabilize after growth, not for initial sprouting or proliferation.
- Mitochondria-derived hydrogen peroxide accumulates during vessel stabilization; NAD suppresses this oxidative threat.
- Blocking NAD synthesis reduced pathological angiogenesis in retinopathy and tumor models.
- Exogenous H2O2 mimics NAD deficiency; antioxidant removal of H2O2 rescues normal vessel quiescence.
- The proliferation-to-quiescence transition is a distinct, targetable phase of angiogenesis.
Methodology
The study combined in vitro endothelial cell culture, ex vivo vascular models, and in vivo mouse models including oxygen-induced retinopathy and tumor angiogenesis. NAD levels were manipulated genetically and pharmacologically, and oxidative stress was assessed via mitochondrial H2O2 measurements.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; detailed methods, statistical analyses, and supplementary data could not be reviewed. Findings are primarily from animal and cell models, and clinical translation will require human trials. Conflict of interest disclosures note that co-author J.A.B. has financial relationships with NAD-related supplement companies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.